Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Thomas J. Schnitzer
- Target Recruit Count
- 17
- Registration Number
- NCT00844480
- Locations
- 🇺🇸
Rehabilitation Institute of Chicago, Chicago, Illinois, United States
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
- Conditions
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT00807963
- Locations
- 🇺🇸
Healthcare Discoveries, LLC/ICON Development Solutions, San Antonio, Texas, United States
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00799266
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Zoledronate for Osteopenia in Pediatric Crohn's
- Conditions
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 13
- Registration Number
- NCT00798473
- Locations
- 🇨🇦
McGill University Health Center - Montreal Children's Hospital, Montreal, Quebec, Canada
Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort
- Conditions
- Interventions
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT00795483
- Locations
- 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
Osteonecrosis of the Hip and Bisphosphonate Treatment
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 120
- Registration Number
- NCT00781261
- Locations
- 🇦🇺
Royal North Shore Hospital, Department of Rheumatology, Sydney, New South Wales, Australia
🇦🇺The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
🇦🇺Princess Alexandra Hospital, Brisbane, Queensland, Australia
Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00774020
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
🇨🇳Novartis Investigative site, Shanghai, China
Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
- Conditions
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-12-07
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00760370
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
🇩🇰Vejle Hospital, Vejle, Denmark
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT00745485
- Locations
- 🇦🇺
Novartis Investigative Site, Nedlands, Australia
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
- Conditions
- Interventions
- Drug: cisplatinDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: ifosfamideDrug: leucovorin calciumDrug: methotrexateDrug: zoledronic acidProcedure: adjuvant therapyProcedure: neoadjuvant therapyProcedure: therapeutic conventional surgeryBiological: filgrastimDrug: Mesna
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 24
- Registration Number
- NCT00742924
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸Maine Children's Cancer Program at Barbara Bush Children's Hospital, Scarborough, Maine, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.